Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEVOSIMENDAN to facilitate weaning from ECMO in severe cardiogenic shock patients
2019-004319-29Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of levosimendan in cardiogenic shock (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Time to successful ECMO weaning. Started Oct 2020; status: completed.
02
Drugs
levosimendan
03
Conditions
cardiogenic shock
Beyond the preview
Go deeper on 2019-004319-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004319-29.